In this day and age of connected living, almost everything imaginable is being adopted into an online activity. One such area transitioning rapidly online is healthcare. The field of digital therapeutics is observing a boost since COVID-19, both, in terms of adoption and investments. The Nordic digital therapeutics company SidekickHealth has established itself as a successful startup and now it has announced securing a multi-million dollar deal partnership with the pharmaceutical giant Pfizer.
SidekickHealth: Empowering patients to take control
Details of the deal between Pfizer and SidekickHealth are yet to be disclosed. However, a source close to the development suggested Silicon Canals that it is somewhere around €7 to €8 million ($8-9 million). This collaboration between the two companies is aimed at empowering patients to take control of their health and focuses on a number of therapeutic areas.
Sidekick co-founder and chief executive officer, Dr. Tryggvi Thorgeirsson, sheds more light on how this partnership will accelerate SidekickHealth’s goals for digital healthcare. He says, ”The deal with Pfizer confirms our belief that digital care will be an integral part of medical treatment going forward, and it shows that our digital therapeutic platform can be scaled across therapeutic areas and geographies with our pharma partners. It also shows the industry is ready to adopt digital care at scale, and is an important step to help accelerate the wider adoption of digital care.”
The partnership will aim its efforts towards patients in Finland suffering from the two main inflammatory bowel disease (IBD) conditions, ulcerative colitis (UC) and Crohn’s disease (CD), followed by patients with rheumatoid arthritis (RA), atopic dermatitis (AD) and psoriatic arthritis (PsA). This year, the digital therapeutics platform will also be made available for UC and RA patients in Sweden, Belgium, Netherlands, Ireland, Switzerland, and Austria, with plans to expand the reach.
“Pfizer continues to be at the forefront of the transformation of medicine, and we share their vision to empower people to better manage their own health and improve their quality of life,” says Thorgeirsson. “Our partnership with Pfizer has the potential to help a vast number of people do just that across multiple geographies, and as such, is precisely what we created Sidekick to do.”
As mentioned earlier, the field of digital therapeutics observed a boost during the COVID-19 lockdown. In an exclusive interview with Silicon Canals, Thorgeirsson says, “Multiple segments of the industry are leaping forward significantly – by several years in many cases. International pharmaceutical firms have been early adopters of digital care partnerships and that trend continues at an accelerated pace. But the biggest change has perhaps been with healthcare providers. That part of the digital care landscape is now really driving digital forward as a direct result of the pandemic.”
Gamified digital therapeutics (DTx) solutions!
SideKickHealth offers gamified DTx solutions that are based on a combination of strong clinical validation with gamification. Rooted in behavioural economics and Artificial Intelligence or (AI), the company’s solutions aim to deliver engaging and personalised experiences. These experiences are scalable across multiple therapeutic areas and induce health behaviour change.
The company was founded back in 2014 by two medical doctors, Tryggvi “Thor” Thorgeirsson, M.D., M.P.H., and Saemundur “Sam” Oddsson, M.D. Treating patients, the duo realised that a staggering 68% of all deaths are due to lifestyle-related illnesses. They devised a new approach to predict and prevent lifestyle-related diseases (chronic disease). Late last year in December, the company announced its partnership with global pharmaceutical and life sciences company Bayer to provide a digital medication management and lifestyle change platform to patients suffering from Peripheral Artery Disease (PAD).
“We founded the company six years ago with a strong belief that digital health solutions could and would expand the reach and impact of traditional treatment of chronic disease. Over the past six years, we have seen the world taking significant steps towards such a future, and this collaboration is an exciting example of that on a large scale,” says Thorgeirsson.